{"name":"Intec Pharma Ltd.","slug":"intec-pharma-ltd","ticker":"","exchange":"","domain":"","description":"Intec Pharma Ltd. is a specialty pharmaceutical company focused on developing and commercializing proprietary drug delivery technologies. The company's lead product candidate, AP-CD/LD, is in phase 3 clinical trials for the treatment of Parkinson's disease.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":6740000,"netIncome":-14128000,"cash":14671000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AP09004","genericName":"AP09004","slug":"ap09004","indication":"Parkinson's disease","status":"phase_2"},{"name":"Accordion Pill™ Carbidopa/Levodopa","genericName":"Accordion Pill™ Carbidopa/Levodopa","slug":"accordion-pill-carbidopa-levodopa","indication":"Parkinson's disease with motor fluctuations","status":"phase_3"},{"name":"Placebo- Sinemet","genericName":"Placebo- Sinemet","slug":"placebo-sinemet","indication":"Parkinson's disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"IN 10 003 formulation B","genericName":"IN 10 003 formulation B","slug":"in-10-003-formulation-b","indication":"Other","status":"phase_2"},{"name":"Placebo -AP-CD/LD","genericName":"Placebo -AP-CD/LD","slug":"placebo-ap-cd-ld","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"AP09004","genericName":"AP09004","slug":"ap09004","phase":"phase_2","mechanism":"AP09004 is a drug that targets the dopamine receptor D2.","indications":["Parkinson's disease"],"catalyst":""},{"name":"Accordion Pill™ Carbidopa/Levodopa","genericName":"Accordion Pill™ Carbidopa/Levodopa","slug":"accordion-pill-carbidopa-levodopa","phase":"phase_3","mechanism":"The Accordion Pill™ is a modified-release formulation that delivers carbidopa and levodopa sequentially to optimize absorption and reduce motor fluctuations in Parkinson's disease.","indications":["Parkinson's disease with motor fluctuations"],"catalyst":""},{"name":"IN 10 003 formulation B","genericName":"IN 10 003 formulation B","slug":"in-10-003-formulation-b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo -AP-CD/LD","genericName":"Placebo -AP-CD/LD","slug":"placebo-ap-cd-ld","phase":"phase_3","mechanism":"AP-CD/LD is a placebo formulation designed to serve as a control comparator in clinical trials, containing no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo- Sinemet","genericName":"Placebo- Sinemet","slug":"placebo-sinemet","phase":"phase_3","mechanism":"Sinemet is a combination of carbidopa and levodopa, which work together to increase dopamine levels in the brain.","indications":["Parkinson's disease","Parkinson's disease with fluctuations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1jeWMwWXotVlNjcjhiLWRTQ2E4T000cjFfX2d0YWFxX0taTzNyZlBZZUJ0SFhvRXo4bEp1VUhkSlRtZ0tmZGFBVFFiQ3RGcnROcXdBQkxMWFZJRjlxdnNER3dZb052NXlX?oc=5","date":"2025-11-26","type":"pipeline","source":"Market.us","summary":"Malaria Ag Rapid Testing Market Growth Analysis | CAGR of 6.1% - Market.us","headline":"Malaria Ag Rapid Testing Market Growth Analysis | CAGR of 6.1%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNa1ZCNlJqWm1HMGJma192eUFmYURyWWhPLWwtS19GQS0wSjAwdUlEdXJPclBaMlZNVjgtZkJIdERPNWZSd28zY29BVmtHRHpBSDdvOWt0R0JXZXV3VnZ5cEZjY1A2N1pNU1dLS29ic2ZuV2ItRldhdzhOa3hma0gyczljUlhHd1AwUlhoRG9VMnlSV0kyVW4tZGdMWlNvc2NpWHFGLVFiVUwyZUlKaUxvYWoyMDlnaUpYU0NBemxGNnlrcGtjM2wyeGpTbUMybVE5VEw0VW1kOFVHWkZCUWZINzE3OXlnQ0FzNlRZNFFTeHZIRjZr?oc=5","date":"2025-08-04","type":"trial","source":"PR Newswire","summary":"Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVGVrai1CM1pnWTc5VnFMVzNSb0ZZQTA2SkZLODBRNGpOSkxucS1ta2NORGxSemc3VUxrSGQyT3c2YlBVckYyMW9Gd1BCRE5keFBycVRBdncycUVmakh6Q014SGVfR2tpcG84a0JHVWRoVi13ME11bEtJM25MUlpMX0I2OWF4MUxDRDR2TlkyUQ?oc=5","date":"2022-10-19","type":"pipeline","source":"Frontiers","summary":"Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia - Frontiers","headline":"Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing ","sentiment":"neutral"},{"date":"2021-08-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2021-07-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2021-07-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2021-07-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2021-06-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2021-05-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2021-04-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE9zd3lyWWxEOTgycjVLbTNsQTB5TEJMSmNKZ24xNVdVbFNQVUtrZnF2czdCa082XzdOTFZ3YkgxTjlwMEtDNTdPVg?oc=5","date":"2020-12-01","type":"deal","source":"StockInvest.us","summary":"Intec Pharma Stock Price Forecast. Should You Buy NTEC? - StockInvest.us","headline":"Intec Pharma Stock Price Forecast. Should You Buy NTEC?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOUkFKYnVsRFFBXzFia242dmJVcDJONmZXLU1wOVRna0JwX0NSTU8yeGFNSGhDdzFZZUl6eVBXQVRfelhuYmtIaWlBSFo2RTUyV1FkcGhLaW02QkRVNUYtbkxHSWdpY3FYbHdDLURibmtrOXdSbEo1S1NoSDhfMEZZT0laeDRfZjhGQU1v?oc=5","date":"2019-09-27","type":"trial","source":"Parkinson's News Today","summary":"Accordion Pill Enables Higher Optimal Doses of Levodopa Than Sinemet, Data Show - Parkinson's News Today","headline":"Accordion Pill Enables Higher Optimal Doses of Levodopa Than Sinemet, Data Show - Parkinson's News Today","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZ3EtbWxBcTBOSmhhQ3V2WVRLVGJIa0p3eHdDZzJEVFRMT2FGbFFZTFFwa0dPc0E4czgtZEEwbjJwZGRxUXgzeWRZTnRxZTdyU016bG0xQjV5S3lMeVB5Z0ltTi10R2RMZjE0d1o0TzFTOHVja2xqMTRLUEdMZWEwUE5xWXVKOENmWncyWmt1SjJ3UmcxWW1wSjZpUFN6N2NSMUdwRUI5NFhpV2Y2RTg2Tm5DLTQzQ0hGRVp3?oc=5","date":"2018-11-12","type":"trial","source":"Parkinson's News Today","summary":"Phase 3 Trial of Accordion Pill in Treating Parkinson’s ‘Off’ Periods Fully Enrolled - Parkinson's News Today","headline":"Phase 3 Trial of Accordion Pill in Treating Parkinson’s ‘Off’ Periods Fully Enrolled - Parkinson's News Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQMk95VTcwZm5tdjVKdHQ3VmlfcXROSURNNmlSVV9QMVRGS2tYTlFXalA2NlhwTy1ESlhNME5ILXVkajc1aVhNMW1aNVlTeURTMVN4Z2tpVkhlcG5OdFRsb0ZBNlJtVm1KMGh2dVJwNUZNN3psSVlOdmh2eE5GT2xUNXphazNKTi1aSEdRNWVSUXptQ091UlBQa2wwZw?oc=5","date":"2018-04-11","type":"pipeline","source":"Globes - Israel Business News","summary":"Intec Pharma raises $35.4m on Nasdaq at 18% discount - Globes - Israel Business News","headline":"Intec Pharma raises $35.4m on Nasdaq at 18% discount - Globes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOQ3lLQ0xaMTZvdHJucWFHd3ItcGpaeFRPSVEwZVBVYk4weGQ2dUxBanVQS2tseGplMi1QSm1XcFJRN2lwWDBWQVBDYnJrMWgtMDZCS212UG1BbHoxV3ZnZldmX3FVdTRjU3lTSGVoUEFVa1hKZzhTQ3VIMFNXRWc0NDdTSnhUU3RRM2NiY2VVUGdaallhSXd1Vk9vWHJHbE0?oc=5","date":"2018-03-15","type":"pipeline","source":"Parkinson's News Today","summary":"Parkinson's Therapy Levodopa's New Formulation to Be Made by Germany's LTS - Parkinson's News Today","headline":"Parkinson's Therapy Levodopa's New Formulation to Be Made by Germany's LTS - Parkinson's News Today","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6740000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-14128000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":14671000,"cashHistory":[],"totalAssets":20896000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}